| Ticker: CVTX | 3172 Porter Drive | |
| Exchange: NASDAQ-National Market | Palo Alto, California 94304 | |
| Industry: Service | (415) 812-0585 |
| Type of Shares: | Common Shares | Filing Date: | 9/25/96 | |
| U.S. Shares: | 1,750,000 | Offer Date: | 11/19/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $10.00 - $12.00 | |
| Primary Shares: | 1,750,000 | Offer Price: | $8.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.56 | |
| Offering Amount: | $19,250,000 | Selling: | $0.32 | |
| Expenses: | - | Reallowance: | $0.10 | |
| Shares Out After: | - |
| Manager | Tier | Phone |
| J.P. Morgan Securities Inc. | Lead Manager | (212) 648-9922 |
| Invemed Associates Inc. | Co-manager | (212) 421-2500 |
| UBS Securities Inc. | Co-manager | (212) 230-4000 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $0.00 | $0.25 | $0.00 | Assets: | $18.21 |
| Net Income: | -$16.72 | -$5.40 | -$8.45 | Liabilities: | $7.88 |
| EPS: | -$4.65 | -$1.25 | -$2.42 | Equity: | $10.33 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a biomedical company focused exclusively on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of chronic cardiovascular diseases. Molecular cardiology was developed, in part, by CVT scientists and their academic collaborators and is based upon the application of molecular biology and genetics to cardiovascular diseases. This discipline has yielded new insights into the mechanisms underlying chronic cardiovascular diseases and has enhanced the search for innovative cardiovascular drugs by providing an increasing number of new molecular targets for drug discovery. To date, CVT has discovered five compounds and completed the strategic in-license of a sixth compound for treatment of chronic cardiovascular diseases. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, including preclinical testing, clinical trials and certain milestone payments; repayment of certain indebtedness; and working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.